Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
Text
Eohilia™ (budesonide) – New orphan drug approval
February 12, 2024 - Takeda announced the FDA approval of Eohilia (budesonide), for 12 weeks of treatment in adult and pediatric patients 11 years of age and older with eosinophilic esophagitis (EoE).
